425 related articles for article (PubMed ID: 20182025)
1. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.
Mosconi L; Berti V; Glodzik L; Pupi A; De Santi S; de Leon MJ
J Alzheimers Dis; 2010; 20(3):843-54. PubMed ID: 20182025
[TBL] [Abstract][Full Text] [Related]
2. FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?
Mosconi L; McHugh PF
Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):250-64. PubMed ID: 21532539
[TBL] [Abstract][Full Text] [Related]
3. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
4. Early detection of Alzheimer's disease using PiB and FDG PET.
Cohen AD; Klunk WE
Neurobiol Dis; 2014 Dec; 72 Pt A():117-22. PubMed ID: 24825318
[TBL] [Abstract][Full Text] [Related]
5. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
6. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
7. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
9. [
Maruyama H; Gomi M; Lwin TT; Yoneyama A; Sasaki T
Ann Nucl Med; 2024 Feb; 38(2):120-130. PubMed ID: 37921921
[TBL] [Abstract][Full Text] [Related]
10. Correlation Between Brain 18F-AV45 and 18F-FDG PET Distribution Characteristics and Cognitive Function in Patients with Mild and Moderate Alzheimer's Disease.
Jing J; Zhang F; Zhao L; Xie J; Chen J; Zhong R; Zhang Y; Dong C
J Alzheimers Dis; 2021; 79(3):1317-1325. PubMed ID: 33427748
[TBL] [Abstract][Full Text] [Related]
11. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
[TBL] [Abstract][Full Text] [Related]
12. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
Sang S; Pan X; Chen Z; Zeng F; Pan S; Liu H; Jin L; Fei G; Wang C; Ren S; Jiao F; Bao W; Zhou W; Guan Y; Zhang Y; Shi H; Wang Y; Yu X; Wang Y; Zhong C
Alzheimers Res Ther; 2018 Mar; 10(1):26. PubMed ID: 29490669
[TBL] [Abstract][Full Text] [Related]
13. Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
Thal DR; Ronisz A; Tousseyn T; Rijal Upadhaya A; Balakrishnan K; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Otto M; Beach TG; Lilja J; Heurling K; Chakrabarty A; Ismail A; Buckley C; Smith APL; Kumar S; Farrar G; Walter J
Acta Neuropathol Commun; 2019 Nov; 7(1):178. PubMed ID: 31727169
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET and amyloid-PET imaging: the diverging paths.
Perani D
Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
[TBL] [Abstract][Full Text] [Related]
16. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
[TBL] [Abstract][Full Text] [Related]
17. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging.
Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J
Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
19. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
[TBL] [Abstract][Full Text] [Related]
20. Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.
Mistur R; Mosconi L; Santi SD; Guzman M; Li Y; Tsui W; de Leon MJ
J Clin Neurol; 2009 Dec; 5(4):153-66. PubMed ID: 20076796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
